MX2014002363A - Formulaciones de antigenos de staphylococcus aureus con adyuvante. - Google Patents

Formulaciones de antigenos de staphylococcus aureus con adyuvante.

Info

Publication number
MX2014002363A
MX2014002363A MX2014002363A MX2014002363A MX2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A MX 2014002363 A MX2014002363 A MX 2014002363A
Authority
MX
Mexico
Prior art keywords
staphylococcus aureus
aureus antigens
adjuvanted formulations
metal salt
aureus
Prior art date
Application number
MX2014002363A
Other languages
English (en)
Inventor
Fabio Bagnoli
Barbara Baudner
Simone Bufali
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002363A publication Critical patent/MX2014002363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se puede mejorar la eficiencia de las vacunas de S. aureus al mezclar con adyuvante antígenos de S. aureus con una mezcla de un agonista de TLR (de manera preferente un agonista de TLR7) y una sal metálica insoluble (de manera preferente una sal de aluminio). El agonista de TLR se adsorbe típicamente a la sal metálica. También se puede absorber un antígeno de S. aureus a la sal metálica.
MX2014002363A 2011-09-01 2012-08-31 Formulaciones de antigenos de staphylococcus aureus con adyuvante. MX2014002363A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
MX2014002363A true MX2014002363A (es) 2014-04-14

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002363A MX2014002363A (es) 2011-09-01 2012-08-31 Formulaciones de antigenos de staphylococcus aureus con adyuvante.

Country Status (14)

Country Link
US (1) US20140363461A1 (es)
EP (1) EP2763695A1 (es)
JP (1) JP2014525429A (es)
KR (1) KR20140066212A (es)
CN (1) CN104093418A (es)
AU (1) AU2012300765A1 (es)
BR (1) BR112014004782A2 (es)
CA (1) CA2847204A1 (es)
IL (1) IL231104A0 (es)
IN (1) IN2014CN02152A (es)
MX (1) MX2014002363A (es)
RU (1) RU2014112343A (es)
SG (1) SG11201400210RA (es)
WO (1) WO2013030378A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859489B2 (en) * 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
CA2825770A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
JP2014525429A (ja) * 2011-09-01 2014-09-29 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
RU2014140336A (ru) * 2012-03-07 2016-04-27 Новартис Аг Иммунологически полезные соли аргинина
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
US9926344B2 (en) * 2012-08-31 2018-03-27 Glaxosmithkline Biologicals Sa Stabilised proteins for immunising against Staphylococcus aureus
WO2014033193A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
ES2769647T3 (es) * 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
RU2337108C2 (ru) 2003-07-24 2008-10-27 Мерк Энд Ко., Инк. Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
CN1980692A (zh) 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
CN1918176A (zh) 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
PL2125792T3 (pl) 2007-02-19 2011-05-31 Glaxosmithkline Llc Pochodne puryny jako immunomodulatory
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US8436178B2 (en) 2007-05-08 2013-05-07 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
BRPI0909037B8 (pt) 2008-03-03 2021-05-25 Irm Llc compostos moduladores da atividade de tlr, e composição farmacêutica
NZ588183A (en) 2008-03-24 2012-05-25 4Sc Discovery Gmbh Novel substituted imidazoquinolines
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
BRPI1013780B8 (pt) * 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
MX2012000044A (es) * 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
US9353160B2 (en) 2009-07-16 2016-05-31 Glaxosmithkline Biologicals S.A. Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
SG178954A1 (en) * 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
US20120177681A1 (en) * 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
ES2681698T3 (es) * 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
JP2014525429A (ja) * 2011-09-01 2014-09-29 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
RU2014140521A (ru) * 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US9926344B2 (en) * 2012-08-31 2018-03-27 Glaxosmithkline Biologicals Sa Stabilised proteins for immunising against Staphylococcus aureus
US20150203543A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
WO2014033193A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2892553A1 (en) * 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
WO2014118305A1 (en) * 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
ES2769647T3 (es) * 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes

Also Published As

Publication number Publication date
JP2014525429A (ja) 2014-09-29
CN104093418A (zh) 2014-10-08
CA2847204A1 (en) 2013-03-07
EP2763695A1 (en) 2014-08-13
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
IN2014CN02152A (es) 2015-09-04
WO2013030378A1 (en) 2013-03-07
SG11201400210RA (en) 2014-03-28
IL231104A0 (en) 2014-04-30
US20140363461A1 (en) 2014-12-11
KR20140066212A (ko) 2014-05-30
RU2014112343A (ru) 2015-10-10

Similar Documents

Publication Publication Date Title
MX2014002363A (es) Formulaciones de antigenos de staphylococcus aureus con adyuvante.
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
EP3071229A4 (en) Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP2680885B8 (en) Combination vaccines with lower doses of antigen and/or adjuvant
HK1202050A1 (en) Lyophilised and aqueous anti-cd40 antibody formulations cd40
IN2014CN04251A (es)
EA201590822A1 (ru) Адъювантная терапия ингибитором киназы семейства tec
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EP2992089A4 (en) Use of anti-cd47 agents to enhance immunization
HK1227279A1 (zh) 在斷奶之前對抗豬繁殖與呼吸綜合徵(prrs)病毒的有效疫苗接種
MX2013001868A (es) Composiciones, formulaciones y metodos de compuestos lipidicos modificadores de respuestas inmunitaria.
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
EP3089754A4 (en) Single vial vaccine formulations
MX2015002482A (es) Composicion inmunogenica.
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
WO2014127378A8 (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
IN2014CN03454A (es)
MY166052A (en) Freeze-Dried Aripiprazole Formulation
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
PL2575872T3 (pl) Zatężanie antygenów szczepionkowych grypy bez liofilizacji
EP2968500A4 (en) VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS